Hiroo Ishida - Northern Yokohama Hospital, Showa University

基本信息

浏览量：55

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 120 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Post-recurrence Survival in Patients with Stage III Gastric Cancer Who Received Adjuvant Chemotherapy; Post-Hoc Analysis of the JACCRO GC-07 Study

Hiroo Ishida,Yu Sunakawa,Yasuhiro Kodera,Kazuhiro Yoshida,Mitsugu Kochi,Yoshihiro Kakeji,Takeshi Sano,Masahiro Takeuchi,Wataru Ichikawa,Masashi Fujii

European journal of cancer (Oxford, England 1990) (2025): 115322-115322

引用0浏览0WOS引用

Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer

Koutaro Ono,Remi Murase,Natsumi Matsumoto,Yutaro Kubota,Hiroo Ishida,Ken-ichi Fujita

Cancer Chemotherapy and Pharmacology（2024）

引用1浏览0WOS引用

Cost-effectiveness Analysis of First Line Pembrolizumab Monotherapy for High Programmed Cell Death Ligand 1 Expressed, Advanced Non-Small Cell Lung Cancer in Japan

Kazuki Tomura,Hiroyuki Sakamaki,Shuichi Nawata,Hiroo Ishida,Katsumi Tanaka,Mari Kogo

International Journal of Clinical Pharmacypp.1-10, (2024)

引用0浏览0WOS引用

Association Between ABCC2 -24C>T and Nab-Paclitaxel-induced Peripheral Neuropathy in Japanese Patients with Pancreatic Cancer

Hana Nakayama,Hiroo Ishida, Masanori Iidaka, Shoko Kato,Kei Nakatani,Akihiro Nakayama,Toshihiro Noguchi,Shigetoshi Nishihara,Shu Oikawa,Tomono Usami,Yuta Mitsui,Yu Ishii,Hirokazu Toshima,Kouji Kobayashi,Remi Murase,Natsumi Matsumoto, Kosuke Suzuki,Ken Shimada,Hitoshi Yoshida, Ken-ichi Fujita

ANTICANCER RESEARCHno. 11 (2024): 5023-5033

引用0浏览0WOS引用

S-1 and CDDP with Concurrent TRT Followed by Durvalumab in Elderly Population with Unresectable, LA-NSCLC in Japan: Post-hoc Analysis of SAMURAI

S. Tanzawa,H. Tanaka,M. Inaba, J. Nakamura, K. Shibata,T. Kishikawa,M. Nakashima,K. Fujiwara,T. Kohyama,H. Ishida,T. Misumi,K. Shiraishi,N. Matsutani,N. Seki, G. Samurai

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S589-S589

引用0浏览0引用

MO3-3 Phase II Study of S-1+CDDP with Concurrent TRT Followed by Durvalumab for Unresectable LA-NSCLC in Japan (SAMURAI)

Shigeru Tanzawa,Hisashi Tanaka,Megumi Inaba,Junya Nakamura,Kazuhiko Shibata,Takayuki Kishikawa,Masanao Nakashima,Keiichi Fujiwara,Tadashi Kohyama,Hiroo Ishida,Toshihiro Misumi,Kenshiro Shiraishi,Noriyuki Matsutani,Nobuhiko Seki

Annals of Oncology (2023): S1396-S1396

引用0浏览0引用

EP08.03-03 S-1 and CDDP with Concurrent TRT Followed by Durvalumab in Elderly Population with Unresectable, LA-NSCLC in Japan: Post-hoc Analysis of SAMURAI

S. Tanzawa, H. Tanaka,M. Inaba, J. Nakamura, K. Shibata,T. Kishikawa,M. Nakashima,K. Fujiwara,T. Kohyama,H. Ishida,T. Misumi,K. Shiraishi,N. Matsutani,N. Seki, G. SAMURAI

Journal of Thoracic Oncologyno. 11 (2023): S589

引用0浏览0引用

Table S1 from Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Toshimitsu Yamaoka,Tohru Ohmori,Motoi Ohba,Satoru Arata,Yasunari Kishino,Yasunori Murata, Sojiro Kusumoto,Hiroo Ishida,Takao Shirai,Takashi Hirose,Tsukasa Ohnishi,Yasutsuna Sasaki

openalex（2023）

引用0浏览0引用

Supplementary Figure 4 from Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation

Toshimitsu Yamaoka,Tohru Ohmori,Motoi Ohba,Satoru Arata,Yasunori Murata,Sojiro Kusumoto,Koichi Ando,Hiroo Ishida,Tsukasa Ohnishi,Yasutsuna Sasaki

openalex（2023）

引用0浏览0引用

Supplementary Figure 5 from Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation

Toshimitsu Yamaoka,Tohru Ohmori,Motoi Ohba,Satoru Arata,Yasunori Murata,Sojiro Kusumoto,Koichi Ando,Hiroo Ishida,Tsukasa Ohnishi,Yasutsuna Sasaki

openalex（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn